Key result
Plasma S-equol over ~5-10 ng/mL is linked to improved cardiovascular biomarkers and clinical outcomes.
Answers are grounded in this paper and cite their sources.
Many clinical studies have been carried out to determine the health benefits of soy protein and the isoflavones contained in soy. S-equol is not present in soybeans but is produced naturally in the gut of certain individuals, particularly Asians, by the bacterial biotransformation of daidzein, a soy isoflavone. In those intervention studies in which plasma S-equol levels were determined, a concentration of >5-10 ng/mL has been associated with a positive outcome for vasomotor symptoms, osteoporosis (as measured by an increase in bone mineral density), prostate cancer, and the cardiovascular risk biomarkers low-density lipoprotein cholesterol and C-reactive protein. These studies suggest that S-equol may provide therapeutic benefits for a number of medical needs.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2011) reported a review. S-equol was evaluated. Plasma S-equol concentrations >5-10 ng/mL were associated with positive outcomes for vasomotor symptoms, osteoporosis, prostate cancer, and cardiovascular risk biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: